Status:
RECRUITING
Healthy Volunteers Study
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Conditions:
Ovarian Cancer
Genetic Predisposition to Disease
Eligibility:
FEMALE
30-50 years
Brief Summary
The purpose of this study is to examine the role of the bacterial environments and metabolites in the early detection and prediction of ovarian cancer development. Vaginal swabs and stool samples will...
Detailed Description
This study will examine the role of the microbiome and its metabolites in early detection and prediction of ovarian cancer development. It has been previously shown that the composition and function o...
Eligibility Criteria
Inclusion
- has ovaries
Exclusion
- genetic mutations which increase risk of ovarian cancer: BRCA1/2, BRIP1, PALB2, Lynch Syndrome (MLH1, MSH2/EPCAM, MSH6) and ATM
- no genetic testing results or unknown genetic status
- prior cancer diagnosis
- prior cancer treatment
- HRT use
- Antibiotic use (1 month prior to providing sample)
Key Trial Info
Start Date :
April 21 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 25 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06962059
Start Date
April 21 2025
End Date
May 25 2026
Last Update
May 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104